Galceran T, Finch J, Bergfeld M, Coburn J, Martin K, Teitelbaum S, Slatopolsky E
Endocrinology. 1987 Jul;121(1):406-13. doi: 10.1210/endo-121-1-406.
Although it is well known that aluminum (Al) plays a role in the development of osteomalacia in patients with chronic renal failure, the mechanisms are not fully understood. Since the osteoblasts are the cells responsible for the formation of osteoid tissue, which is greatly affected in patients with Al-induced osteomalacia, it is possible that Al could affect the number of osteoblasts or interfere with their function. To further characterize this potential mechanism, we performed studies in isolated perfused tibiae from normal and Al-treated dogs. In this system, when PTH is added to the perfusate, cAMP, a major marker of osteoblasts, is released. The dogs were divided into two groups: control, and Al-treated (0.75 mg/kg, iv, 5 days a week for 3 months). Thereafter, the dogs were killed, and the tibiae were perfused in vitro. PTH-(1-34) (3-4 ng/ml) and 3-isobutyl-1-methylxanthine (an inhibitor of phosphodiesterase) were added to the perfusate. Basal cAMP secretion was the same in both groups of dogs. After PTH was added to the perfusate, cAMP increased to a peak of 188.2 +/- 30.6 pmol/min in the normal dogs vs. 113 +/- 8.15 in Al-treated dogs (P less than 0.05). Cumulative cAMP secretion over a 30-min period was 766 +/- 127.9 pmol in the normal dogs vs. 455.6 +/- 38.2 pmol in the experimental animals (P less than 0.05). The histological appearance of bone biopsies taken before and after Al administration are consistent with a suppressive effect of the cation on osteoblast function. In particular, the number of osteoblasts had decreased 8-fold (P less than 0.01) under the influence of Al, and tetracycline-based measurements of mineralization kinetics show that osteoblast-mediated calcification was dysfunctional (P less than 0.01-0.025). On the other hand, the histological features of the post Al treatment biopsies suggest that at some time during its administration, the cation stimulates osteoblastic activity. For example, new (woven) bone formation was present in two dogs, and in another, lamellar bone, deposited under the influence of Al, covered the entire trabecular surface. Moreover, Al-associated osteoid was deposited independent of prior resorptive activity, indicating that the cation promotes bone formation in the absence of prior resorption. In keeping with its trophic effect on matrix deposition, Al also led to extensive marrow fibrosis in five dogs, indicating that Al also stimulates the activity of fibroblasts, cells closely related to osteoblasts.(ABSTRACT TRUNCATED AT 400 WORDS)
虽然众所周知铝(Al)在慢性肾衰竭患者骨软化症的发展中起作用,但其机制尚未完全明确。由于成骨细胞是负责类骨质组织形成的细胞,而在铝诱导的骨软化症患者中该组织受到极大影响,所以铝有可能影响成骨细胞数量或干扰其功能。为进一步明确这一潜在机制,我们对正常犬和经铝处理的犬的离体灌注胫骨进行了研究。在该系统中,当向灌注液中添加甲状旁腺激素(PTH)时,成骨细胞的主要标志物环磷酸腺苷(cAMP)会被释放出来。犬被分为两组:对照组和经铝处理组(0.75毫克/千克,静脉注射,每周5天,共3个月)。此后,处死犬,然后对胫骨进行体外灌注。向灌注液中添加PTH - (1 - 34)(3 - 4纳克/毫升)和3 - 异丁基 - 1 - 甲基黄嘌呤(一种磷酸二酯酶抑制剂)。两组犬的基础cAMP分泌量相同。向灌注液中添加PTH后,正常犬的cAMP增加至峰值188.2±30.6皮摩尔/分钟,而经铝处理的犬为113±8.15(P<0.05)。在3〇分钟内正常犬的累积cAMP分泌量为766±127.9皮摩尔,而实验动物为455.6±38.2皮摩尔(P<0.05)。铝给药前后所取骨活检的组织学表现与该阳离子对成骨细胞功能的抑制作用一致。特别是,在铝的影响下成骨细胞数量减少了8倍(P<0.01),基于四环素的矿化动力学测量表明成骨细胞介导的钙化功能失调(P<0.01 - 0.025)。另一方面,铝处理后活检的组织学特征表明,在给药过程中的某个时间点,该阳离子会刺激成骨细胞活性。例如,两只犬出现了新的(编织状)骨形成,在另一只犬中,在铝的影响下沉积的板层骨覆盖了整个小梁表面。此外,与铝相关的类骨质沉积与先前的吸收活动无关,这表明该阳离子在没有先前吸收的情况下促进骨形成。与其对基质沉积的营养作用一致,铝还导致五只犬出现广泛的骨髓纤维化,这表明铝也刺激了与成骨细胞密切相关的成纤维细胞的活性。(摘要截短至400字)